We present a case of 23 years multigravid woman (G2P0+1) with chronic idiopathic thrombocytopenic purpura (ITP), refractory to treatment in forms of oral steroid, dapsone, azathioprine and splenectomy. She presented to the hospital in third trimester of pregnancy, with reduced platelet counts and purpuric rashes over abdomen and both upper extremeties. There was a past history of spontaneous abortion at 18 weeks. The patient responded to intravenous high dose methylprednisolone (HDMP) infusion leading to delivery of full term male baby. The baby also required treatment for thrombocytopenia with intravenous immunoglobulin (IVIG). This case lays down the importance of HDMP in form of using it effectively in managing acute crisis of low platelet counts in pregnant patients with ITP refractory to splenectomy.

**Keywords**: chronic idiopathic thrombocytopenic purpura, intravenous immunoglobulin, methylprednisolone, splenectomy.

---

**INTRODUCTION**

Idiopathic thrombocytopenic purpura with an overall incidence of 1.6 per 100,000 per year is particularly more common in women of child bearing age group. In pregnant women ITP is the most common cause of thrombocytopenia in first and second trimester of pregnancy affecting 1 to 2 women of every 10,000 pregnancies. ITP is an autoimmune disorder, where platelets are destroyed due to binding of platelet autoantibodies to the antigen on platelet surface. These platelet autoantibodies can also cross placenta and are responsible for thrombocytopenia in some infants. Chronic ITP refractory to splenectomy in obstetrics poses a life threatening hemostatic risk during delivery hence managing such type of patient is a real challenge. We report here a case of management of acute crisis of low platelets in a pregnant female of chronic ITP refractory to splenectomy.

**CASE**

A 23 years multigravid patient (G2P0+1) in her third trimester (at 33 weeks gestation) of pregnancy, weight 62 kg and blood group O Rh(D) positive, presented to our hospital with chief complaints of purpuric rashes over anterior abdomen and both upper extremeties with epistaxis since last one week. The patient responded to intravenous high dose methylprednisolone (HDMP) infusion leading to delivery of full term male baby. The baby also required treatment for thrombocytopenia with intravenous immunoglobulin (IVIG). This case lays down the importance of HDMP in form of using it effectively in managing acute crisis of low platelet counts in pregnant patients with ITP refractory to splenectomy.

**Keywords**: chronic idiopathic thrombocytopenic purpura, intravenous immunoglobulin, methylprednisolone, splenectomy.
Laboratory test yielded the following results: haemoglobin 11.9g/dl (12-15 g/dl), total WBC count 11.4 x 10^9/l (4-10 x 10^9/l), hematocrit 39.5 % (45-50%), platelets 10 x 10^9/l (150 - 400 x 10^9/l), MCV 82.3 fl (83-101 fl), MCH 24.6 pg (27-31 pg), MCHC 29.8% (31.5-34.5%). PT/INR were within reference range. Blood borne virus screen for HIV, HbsAg, and HCV was negative.

Due to non-affordability, immunoglobulin or anti-D could not be given. The patient was started on high dose (1 gm intravenous infusion per day for 3 days) methylprednisolone (HDMP). The platelet counts increased to a level of 60,000/cumm on third day after starting HDMP (Figure 1).

![Figure 1. Platelet count of patient with treatment.](image)

Thereafter patient was maintained on tapering dose of oral steroid for further three weeks and caesarean section was planned at 38 weeks with transfusion of single donor platelets (SDP) on the day of surgery. Male baby 3179 gm was delivered. Baby was also thrombocytopenic with platelet counts of 46 x 10^9/l. Baby responded to immunoglobulin treatment with platelet counts increasing up to 78 x 10^9/l. Mother and baby were discharged with platelet counts of 89 x 10^9/l and 91 x 10^9/l respectively.

**DISCUSSION**

Thrombocytopenia is the second most common hematological abnormality during pregnancy after anaemia.\(^5\) Thrombocytopenia during pregnancy due to physiological causes accounts for almost three fourths of all cases, and is often referred to as gestational thrombocytopenia. It may be secondary to accelerated platelet consumption and increased plasma volume associated with pregnancy. It is considered as a diagnosis of exclusion, and the following characteristics make gestational thrombocytopenia more likely: (1) the degree of thrombocytopenia is usually mild, usually remaining greater than 70,000 µL; (2) patients are asymptomatic with no history of bleeding and presenting usually in third trimester; (3) there is no preconception history of thrombocytopenia; (4) an early gestation or preconception platelet count is normal.\(^6\)

Immune thrombocytopenic purpura incorporates pathological causes of thrombocytopenia in pregnancy, mainly comprising immune mediated platelet destruction. In acute form, it is usually self-limiting and mostly affecting children. When chronic, it predominately affects women in their second to third decades of life, and accounts for 3% of all cases of thrombocytopenia during pregnancy.\(^7\)

The optimal treatment strategies for ITP in pregnancy still remain controversial. Therapy of the pregnant woman with ITP is very similar to that of non-pregnant individual. Therapeutic interventions are usually started when platelet counts reach unacceptably low values (approximately 30,000/uL), or when the patient exhibits signs of bleeding, such as petechiae, purpura, or epistaxis.\(^8\) Prednisolone (1 mg/kg) remains the first line of therapy for pregnant women with ITP, and the response to therapy is very much the same as that observed in non-pregnant individuals, with an overall response rate of 60% to 70%.\(^8\) However, since steroid is not free from various side effects, IV immunoglobulins (IVIG) (1 gm/kg once daily for 2 days) can be used alternatively which is considered as standard therapy by many experts for pregnancy associated thrombocytopenia due to its low toxicity profile.\(^9\) However, as IVIG due to its short lasting effect and high cost cannot be used in most of the patients. Intravenous anti-D, in a dose of 50-70 microgram/kg, having similar efficacy and toxicity profile as IVIG, and can also be used as second line therapy in patients not tolerating IVIG and/or steroid.\(^10\) Although it is cheaper than IVIG, it is still beyond the reach of most patients in India.

Use of HDMP (30 mg/kg for 3 days) as first line therapy in the management of ITP and also in patients not responding to conventional dose prednisolone (1 mg/kg/day) has been well documented. HDMP has...
also been demonstrated to be effective in ITP patients refractory to IVIG and oral prednisolone.\textsuperscript{11} Narang et al\textsuperscript{12} have used HDPM successfully for managing acute crisis of thrombocytopenia, in third trimester of pregnancy of a non-splenectomized female suffering from ITP. Splenectomy which is considered as the standard treatment for ITP in adults has a response rate of 66\%.\textsuperscript{13} Strategies for treating a post-splenectomy refractory ITP still remains unexplored. We found HDMP to be effective in post-splenectomy refractory ITP. Hence we recommend using HDM in case of post-splenectomy refractory ITP during emergency situations.

ITP may affect both the mother and fetus, and the offspring of the patient with ITP may also develop thrombocytopenia, due to transplacental passage of maternal platelet autoantibodies.\textsuperscript{4} Hence active management of new born during first week of birth with IVIG should be considered.

\textbf{ACKNOWLEDGEMENT}

We thank Dr Dipanwita Sen, department of obstetrics and gynaecology of The Mission Hospital, Durgapur for her valuable support in providing relevant clinical details.

\textbf{DISCLOSURE}

The authors report no conflicts of interest in this work.

No violation of human rights and safety.

Funding: Nil

\textbf{REFERENCES}